Walker P - Search Results

1

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.

Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, Spencer A, Ritchie D, Agarwal R, Blombery P. Tam CS, et al. Among authors: walker p. Intern Med J. 2022 Jul;52(7):1286-1287. doi: 10.1111/imj.15851. Intern Med J. 2022. PMID: 35879233 No abstract available.

2

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A. Low M, et al. Among authors: walker p. Intern Med J. 2013 Mar;43(3):294-7. doi: 10.1111/j.1445-5994.2012.02868.x. Intern Med J. 2013. PMID: 22757980 Review.

3

Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.

Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Govindaraj C, et al. Among authors: walker p. Clin Cancer Res. 2014 Feb 1;20(3):724-35. doi: 10.1158/1078-0432.CCR-13-1576. Epub 2013 Dec 2. Clin Cancer Res. 2014. PMID: 24297862 Clinical Trial.

4

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A. Tan P, et al. Among authors: walker p. Blood Cancer J. 2014 Jan 10;4(1):e170. doi: 10.1038/bcj.2013.68. Blood Cancer J. 2014. PMID: 24413064 Free PMC article.

5

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma.

Campbell P, Walker P, Avery S, Patil S, Curtis D, Schwarer A, Wei A, Kalff A, Muirhead J, Spencer A. Campbell P, et al. Among authors: walker p. Blood Cancer J. 2014 May 9;4(5):e213. doi: 10.1038/bcj.2014.33. Blood Cancer J. 2014. PMID: 24813081 Free PMC article. No abstract available.

6

Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.

Doan TN, Kong DC, Patel K, Walker P, Spencer A, Kirkpatrick CM. Doan TN, et al. Among authors: walker p. Int J Antimicrob Agents. 2014 Nov;44(5):450-7. doi: 10.1016/j.ijantimicag.2014.07.019. Epub 2014 Sep 6. Int J Antimicrob Agents. 2014. PMID: 25261159

7

Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.

Morrissey CO, Gilroy NM, Macesic N, Walker P, Ananda-Rajah M, May M, Heath CH, Grigg A, Bardy PG, Kwan J, Kirsa SW, Slavin M, Gottlieb T, Chen S. Morrissey CO, et al. Among authors: walker p. Intern Med J. 2014 Dec;44(12b):1298-314. doi: 10.1111/imj.12596. Intern Med J. 2014. PMID: 25482742 Review.

8

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.

Pham T, Patil S, Fleming S, Avery S, Walker P, Wei A, Curtis D, Stuart G, Klarica D, O'Brien M, Morris K, Das T, Bollard G, Muirhead J, Coutsouvelis J, Spencer A. Pham T, et al. Among authors: walker p. Transfusion. 2015 Nov;55(11):2709-13. doi: 10.1111/trf.13233. Epub 2015 Jul 14. Transfusion. 2015. PMID: 26173921

9

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

Doan TN, Kirkpatrick CM, Walker P, Slavin MA, Ananda-Rajah MR, Morrissey CO, Urbancic KF, Grigg A, Spencer A, Szer J, Seymour JF, Kong DC. Doan TN, et al. Among authors: walker p. J Antimicrob Chemother. 2016 Feb;71(2):497-505. doi: 10.1093/jac/dkv343. Epub 2015 Oct 30. J Antimicrob Chemother. 2016. PMID: 26518050

10

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A. Nair AP, et al. Among authors: walker p. Bone Marrow Transplant. 2017 Jun;52(6):839-845. doi: 10.1038/bmt.2017.37. Epub 2017 Mar 20. Bone Marrow Transplant. 2017. PMID: 28319080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,086 results

Search Page